Document is current
Any future updates will be listed below
-
Authors
Perera, Rashindrie https://orcid.org/0000-0001-6822-2900
Savas, Peter
Senanayake, Damith
Salgado, Roberto https://orcid.org/0000-0002-1110-3801
Joensuu, Heikki https://orcid.org/0000-0003-0281-2507
O’Toole, Sandra
Li, Jason
Loi, Sherene https://orcid.org/0000-0001-6137-9171
Halgamuge, Saman
- License Information
-
More Information
Article History
Received: 29 November 2023
Accepted: 2 July 2024
First Online: 25 July 2024
Competing interests
: The authors declare the following competing interests: S.L. receives research funding to her institution from Novartis, Bristol Meyers Squibb, Merck, Puma Biotechnology, Eli Lilly, Nektar Therapeutics, Astra Zeneca, Roche-Genentech, and Seattle Genetics. She has acted as consultant (not compensated) to Seattle Genetics, Novartis, Bristol Meyers Squibb, Merck, AstraZeneca, Eli Lilly, Pfizer, Gilead Therapeutics and Roche-Genentech. She has acted as consultant (paid to her institution) to Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, Astra Zeneca, Silverback Therapeutics, G1 Therapeutics, PUMA Biotechnologies, Pfizer, Gilead Therapeutics, Seattle Genetics, Daiichi Sankyo, Merck, Amunix, Tallac Therapeutics, Eli Lilly, and Bristol Meyers Squibb. R.S. reports research funding by Roche, Merck, and Puma Biotechnology; travel and congress-registration support by Roche, Merck, and Astra Zeneca; and was part of Advisory Boards for Bristol Myers Squibb and Roche. H.J. HJ is the Chairman of the Scientific Advisory Board, Orion Pharma; the Chairman of the Scientific Advisory Board, Neutron Therapeutics; has received a payment for a lecture from Deciphera Pharmaceuticals; owns stock of Sartar Therapeutics and Orion Pharma.
